纤维蛋白原与乳腺癌患者预后关系的Meta分析

doi:10.13481/j.1671-587x.20190521

摘要/Abstract

摘要： 目的：采用Meta分析方法探讨纤维蛋白原（Fib）表达水平与乳腺癌患者预后的关系，为乳腺癌患者预后判断提供循证医学依据。方法：检索PubMed、EMbase、Cochrane图书馆和中国知网（CNKI）等数据库有关Fib与乳腺癌患者预后关系的研究，检索时限均为建库至2019年1月。由2名研究员按纳入和排除标准进行数据提取，使用STATA 14.0软件对数据进行Meta分析。结果：最终纳入8篇病例对照研究，共158 204例患者。纳入研究的异质性检验，I²=58.4%，P=0.019，故采用随机效应模型进行分析。Fib高表达水平与乳腺癌患者低总生存期（OS）有关[相对风险比（HR）=1.37，95％置信区间（CI）：1.14，1.64，Z=3.36，P=0.001]；Fib高表达水平与亚洲组乳腺癌患者低OS有关（HR=1.83，95％CI：1.23，2.72，Z=3.00，P=0.003）。敏感性分析，纳入8项研究结果稳定可信；Begg’s检验，Z=1.61，P=0.108，无明显的发表偏倚。结论：高表达水平的Fib与乳腺癌患者预后不良明显关联。

关键词: 纤维蛋白原, 乳腺肿瘤, 预后, Meta分析

Abstract: Objective::To investigate the relationship between the expression level of fibrinogen (Fib) and the prognosis of breast cancer patients with Meta-analysis, and to provide evidence-based medical evidence for the judgement of prognosis of the breast cancer patients. Methods:PubMed, EMbase, Cochrane Library and CNKI databases were searched for collecting the studies about the relationship between Fib and prognosis of the breast cancer patients from inception to January 2019. Two reviewers extracted the data according to inclusion and exclusion criteria. Meta-analysis was performed by using Stata 14.0 software. Results:A total of 158 204 patients from 8 case-control studies were included.The heterogeneity test results included in the studies were I²=58.4%,P=0.019, and the data were analyzed using a random effect model. The results suggested that high expression level of Fib was associated with the lower overall survival (OS) in the breast cancer patients(HR=1.37, 95%CI:1.14,1.64, Z=3.36,P=0.001).The high expression level of Fib was associated with the lower OS in the Asia breast cancer patients(HR=1.83, 95%CI:1.23,2.72, Z=3.00,P=0.003).The sensitivity analysis results showed that the results of 8 included studies were stable and reliable; Begg's test, Z=1.61,P=0.108, suggesting that there was no obvious publication bias. Conclusion:High expression level of Fib is significantly associated with the poor prognosis in the breast cancer patients.

Key words: fibrinogen, breast neoplasms, prognosis, Meta-analysis

中图分类号:

R737.9

于秀艳, 万广财, 孙洪帅, 朱华, 高海燕, 吴雪峰. 纤维蛋白原与乳腺癌患者预后关系的Meta分析[J]. 吉林大学学报(医学版), 2019, 45(05): 1092-1097.

YU Xiuyan, WAN Guangcai, SUN Hongshuai, ZHU Hua, GAO Haiyan, WU Xuefeng. Relationship between fibrinogen and prognosis of breast cancer patients:A Meta-analysis[J]. Journal of Jilin University(Medicine Edition), 2019, 45(05): 1092-1097.

参考文献

[1] 陈莉莉,石菊芳,刘玉琴,等. 基于人群的乳腺癌预后参数研究现状[J]. 中华乳腺病杂志:电子版, 2018, 12(6):370-372.
[2] 方程. 乳腺癌MCF-7细胞他莫昔芬耐药株的建立及不同细胞株之间的miRNA差异性表达[D]. 武汉:武汉大学, 2017.
[3] 李新方,王骐榕,杨峰. 纳米材料在乳腺癌靶向治疗中的应用进展[J]. 山东医药,2018,58(39):96-100.
[4] 胥芸芸,翟振兴,李桂香.血浆纤维蛋白表达水平与肾细胞癌风险相关性的Meta分析[J].中国循证医学杂志,2017,17(5):529-535.
[5] 黄武浩. Fib联合中性粒细胞与淋巴细胞比值对非小细胞肺癌的预后价值[D].天津:天津医科大学,2018.
[6] 阳圆圆. 二甲双胍延长乳腺癌合并糖尿病患者总生存的Meta分析[D].南昌:南昌大学,2018.
[7] 孙无悔. 血脂水平与胰腺癌发病风险、临床特征及术后短期结局关系研究[D].杭州:浙江大学,2018.
[8] SONG H F, KUANG G Y, ZHANG Z N, et al. The prognostic value of pretreatment plasma fibrinogen in urological cancers:a systematic review and Meta-analysis[J].JCancer,2019,10(2):479-487.
[9] STANG A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9):603-605.
[10] XIA WJ, CHEN WZ, ZHANG ZG, et al. Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer:A meta-analysis[J]. PLoS One, 2015, 10(4):e0123484.
[11] KABAT G C, SALAZAR C R, ZASLAVSKY O, et al. Longitudinal association of hemostatic factors with risk for cancers of the breast, colorectum, and lung among postmenopausal women[J]. Eur J Cancer Prev, 2016, 25(5):449-456.
[12] KRENN-PILKO S,LANGSENLEHNERU,STOJAKOVICT,et al. An elevated preoperative plasma fibrinogen level is associated with poor disease-specific and overall survival in breast cancer patients[J]. Breast, 2015, 24(5):667-672.
[13] WEN J H, YANG Y N, YE F,et al. The preoperative plasma fibrinogen level is an independent prognostic factor for overall survival of breast cancer patients who underwent surgical treatment[J]. Breast, 2015, 24(6):745-750.
[14] ALLIN K H, BOJESEN S E, NORDESTGAARD B G. Inflammatory biomarkers and risk of cancer in 84000 individuals from the general population[J]. Int J Cancer, 2016,139(7):1493-1500.
[15] MEI Y,ZHAO S, LU X F, et al. Clinical and prognostic significance of preoperative plasma fibrinogen levels in patients with operable breast cancer[J]. PLoS One, 2016, 11(1):e0146233.
[16] TOBIAS D K, AKINKUOLIE A O, CHANDLER P D, et al. Markers of inflammation and incident breast cancer risk in the women's health study[J]. Am J Epidemiol, 2018, 187(4):705-716.
[17] GRAF M E, SOOKTHAI D, JOHNSON T, et al. Pre-diagnostic plasma concentrations of Fibrinogen, sGPⅡb/Ⅲa, sP-selectin, sThrombomodulin, Thrombopoietin in relation to cancer risk:Findings from a large prospective study[J]. Int J Cancer, 2018, 143(11):2659-2667.
[18] 刘华,杨贵义,李新新,等.术前中性粒细胞与淋巴细胞比值联合纤维蛋白原与乳腺癌患者预后的关系[J].癌症进展,2018,16(12):1522-1524, 1553.
[19] 岳丰莉,潘沁汶,邓长容.延长辅助内分泌治疗对比5年标准治疗对雌激素受体阳性早期乳腺癌患者预后影响的Meta分析[J].中华乳腺病杂志:电子版,2018,12(1):37-42.
[20] 徐晶. 甲状腺功能减退与乳腺癌相关性的Meta分析[D].太原:山西医科大学,2018.
[21] 邵建斌,杨梅兰.miR-198靶向MAPK1对人乳腺癌MCF-7细胞增殖和凋亡的调控作用[J].中国肿瘤生物治疗杂志,2018,25(12):1259-1263.
[22] SAHNI A, SIMPSON-HAIDARIS P J,SAHNI S K, et al. Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2(FGF-2)[J]. J Thromb Haemost, 2008, 6(1):176-183.
[23] ZHENG S, SHEN J, JIAO Y, et al. Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity[J]. Cancer Sci, 2009, 100(5):859-865.
[24] SHU Y J, WENG H, BAO R F, et al. Clinical and prognostic significance of preoperative plasma hyperfibrinogenemia in gallbladder cancer patients following surgical resection:A retrospective and in vitro study[J]. BMC Cancer, 2014,14(1):566.
[25] 张会珍,孙煜.高频彩色多普勒超声联合血清纤维蛋白原及CA199检测在乳腺癌术前诊断中的应用[J].中国医学装备,2018,15(7):76-79.
[26] 梅玉. 乳腺癌患者血清中纤维蛋白原水平及其在癌组织中表达的临床研究[D].济南:山东大学,2016.
[27] 方双双,王若雨.血浆Fib在乳腺癌中的研究进展[J].中国实用医药,2019,14(6):195-197.
[28] FU S, YUN Z Y, CUI M M, et al. Cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients[J]. Oncotarget, 2017, 8(40):67829-67836.
[29] HWANG K T,CHUNG J K,ROH E Y, et al. Prognostic influence of preoperative fibrinogen to albumin ratio for breast cancer[J]. J Breast Cancer, 2017, 20(3):254-263.